Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Abstract Introduction Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. M...

Full description

Bibliographic Details
Main Authors: Mark L. Wencel, Tmirah Haselkorn, Susan L. Limb, John L. Stauffer, Elizabeth Morgenthien, Karina Raimundo, Peter P. LaCamera
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-06-01
Series:Pulmonary Therapy
Subjects:
Adverse event management
Antifibrotic therapy
Idiopathic pulmonary fibrosis
Pirfenidone
Real-world
Titration
Online Access:https://doi.org/10.1007/s41030-018-0056-8

Internet

https://doi.org/10.1007/s41030-018-0056-8

Similar Items